$MNMD
Mind Medicine (MindMed) Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058248 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.164M $13.20M
YoY Change -77.04% 43.31%
% of Gross Profit
Research & Development $21.04M $13.20M
YoY Change 162.03% 69.88%
% of Gross Profit
Depreciation & Amortization $790.0K $790.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $22.21M $21.62M
YoY Change 59.75% 27.28%
Operating Profit -$21.62M
YoY Change 27.28%
Interest Expense $1.306M $720.0K
YoY Change 13.27% 44.58%
% of Operating Profit
Other Income/Expense, Net -$2.965M $3.693M
YoY Change -137.8% 641.57%
Pretax Income -$23.86M -$17.92M
YoY Change 386.72% 8.7%
Income Tax
% Of Pretax Income
Net Earnings -$23.86M -$17.92M
YoY Change 386.72% 8.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$0.59 -$0.45
COMMON SHARES
Basic Shares Outstanding 40.09M 39.72M
Diluted Shares Outstanding 39.72M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.70M $117.7M
YoY Change -29.86% -23.83%
Cash & Equivalents $99.70M $117.7M
Short-Term Investments
Other Short-Term Assets $4.168M $2.400M
YoY Change 6.52% 20.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $103.9M $120.1M
YoY Change -28.88% -23.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $19.92M $19.92M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $224.0K $229.0K
YoY Change -32.33%
Total Long-Term Assets $20.67M $21.46M
YoY Change -13.66% -12.02%
TOTAL ASSETS
Total Short-Term Assets $103.9M $120.1M
Total Long-Term Assets $20.67M $21.46M
Total Assets $124.5M $141.6M
YoY Change -26.74% -21.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.136M $7.686M
YoY Change 95.93% 832.77%
Accrued Expenses $11.63M $9.957M
YoY Change 97.96% 33.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.25M $31.15M
YoY Change 80.23% 19.65%
LONG-TERM LIABILITIES
Long-Term Debt $14.13M $14.07M
YoY Change
Other Long-Term Liabilities $32.00K $349.0K
YoY Change -97.3% -72.65%
Total Long-Term Liabilities $14.16M $14.42M
YoY Change 1096.03% 1029.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.25M $31.15M
Total Long-Term Liabilities $14.16M $14.42M
Total Liabilities $46.41M $45.57M
YoY Change 143.27% 66.84%
SHAREHOLDERS EQUITY
Retained Earnings -$290.2M -$266.3M
YoY Change 49.2% 40.45%
Common Stock $368.0M $361.5M
YoY Change 6.74% 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.13M $95.98M
YoY Change
Total Liabilities & Shareholders Equity $124.5M $141.6M
YoY Change -26.74% -21.76%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$23.86M -$17.92M
YoY Change 386.72% 8.72%
Depreciation, Depletion And Amortization $790.0K $790.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$20.56M -$16.62M
YoY Change 60.04% 78.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.593M 17.40M
YoY Change 523.32% -70.11%
NET CHANGE
Cash From Operating Activities -20.56M -16.62M
Cash From Investing Activities
Cash From Financing Activities 2.593M 17.40M
Net Change In Cash -17.97M 780.0K
YoY Change 44.53% -98.41%
FREE CASH FLOW
Cash From Operating Activities -$20.56M -$16.62M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001813814
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q3 us-gaap Warrants And Rights Outstanding Valuation Technique Extensible List
WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
CY2022Q4 us-gaap Warrants And Rights Outstanding Valuation Technique Extensible List
WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40360
dei Entity Registrant Name
EntityRegistrantName
Mind Medicine (MindMed) Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1582538
dei Entity Address Address Line1
EntityAddressAddressLine1
One World Trade Center
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 8500
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-6633
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
MNMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40094708
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117699000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142142000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2387000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3913000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
120086000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
146055000
CY2023Q3 us-gaap Goodwill
Goodwill
19918000
CY2022Q4 us-gaap Goodwill
Goodwill
19918000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1317000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
3689000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
229000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
331000
CY2023Q3 us-gaap Assets
Assets
141550000
CY2022Q4 us-gaap Assets
Assets
169993000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7686000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2111000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9957000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5877000
CY2023Q3 mnmd Financing Warrants Liability
FinancingWarrantsLiability
13511000
CY2022Q4 mnmd Financing Warrants Liability
FinancingWarrantsLiability
9904000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31154000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17892000
CY2023Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
14068000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
349000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1184000
CY2023Q3 us-gaap Liabilities
Liabilities
45571000
CY2022Q4 us-gaap Liabilities
Liabilities
19076000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40094708
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40094708
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37979136
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37979136
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
361538000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
344758000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
777000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
627000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266336000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194468000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
95979000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
150917000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141550000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169993000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13203000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7772000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40578000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27339000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8413000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9211000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31083000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25092000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
21616000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
16983000
us-gaap Operating Expenses
OperatingExpenses
71661000
us-gaap Operating Expenses
OperatingExpenses
52431000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21616000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16983000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71661000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52431000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1163000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
360000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3759000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
443000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-439000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
138000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-244000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
94000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3020000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3671000
CY2023Q3 us-gaap Other Income
OtherIncome
-51000
us-gaap Other Income
OtherIncome
-51000
us-gaap Other Income
OtherIncome
1000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3693000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
498000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-207000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
538000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-17923000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16485000
us-gaap Net Income Loss
NetIncomeLoss
-71868000
us-gaap Net Income Loss
NetIncomeLoss
-51893000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
415000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-107000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
150000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-303000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17508000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16592000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71718000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52196000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39720007
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39720007
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29296333
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29296333
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38798374
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38798374
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28566161
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28566161
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
150917000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4943000
mnmd Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
178000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11610000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71718000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
95979000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
151664000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41350000
mnmd Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
708000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
206000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-407000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12268000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52196000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
153593000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
105972000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3086000
CY2023Q3 mnmd Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
178000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4202000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17508000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
95979000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
124504000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41350000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4289000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16592000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
153593000
us-gaap Profit Loss
ProfitLoss
-71868000
us-gaap Profit Loss
ProfitLoss
-51893000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11818000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12331000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2372000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2390000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3671000
mnmd Issuance Costs On Liability Classified Warrants
IssuanceCostsOnLiabilityClassifiedWarrants
1500000
mnmd Other Non Cash Adjustments
OtherNonCashAdjustments
128000
mnmd Other Non Cash Adjustments
OtherNonCashAdjustments
30000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1575000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1837000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-60000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5535000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3329000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3742000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
622000
mnmd Other Liabilities Long Term
OtherLiabilitiesLongTerm
835000
mnmd Other Liabilities Long Term
OtherLiabilitiesLongTerm
778000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43802000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37290000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
15000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
802000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4943000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41567000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
17747000
mnmd Payment Of Financing Warrants Issuance Costs
PaymentOfFinancingWarrantsIssuanceCosts
1186000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
114000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
708000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
407000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19255000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58635000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
104000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-365000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24443000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20980000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142142000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
133539000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
117699000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
154519000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
170000
us-gaap Stock Issued1
StockIssued1
64000
mnmd Proceeds From Exercise Of Options In Prepaid And Other Current Assets
ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets
49000
mnmd Unpaid Issuance Costs For Common Shares
UnpaidIssuanceCostsForCommonShares
217000
mnmd Unpaid Issuance Costs For Financing Warrants
UnpaidIssuanceCostsForFinancingWarrants
314000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
194000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF THE BUSINESS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mind Medicine (MindMed) Inc. (the “Company” or “MindMed”) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (“MindMed US”), HealthMode Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company’s mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company’s lead product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">266.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Through September 30, 2023, all the Company’s financial support has primarily been provided by proceeds from the issuance of the Company’s common shares (the “Common Shares”) and warrants to purchase Common Shares and the credit facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements.</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board ("FASB") standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company.</span></p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266300000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
115300000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
131700000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2023Q3 mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
CY2022Q3 mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
mnmd Indication Of Impairment Of Goodwill And Long Lived Assets
IndicationOfImpairmentOfGoodwillAndLongLivedAssets
0
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9485000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8168000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1317000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9485000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5796000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3689000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3502000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3198000
CY2023Q3 mnmd Accrued Clinical And Manufacturing Costs
AccruedClinicalAndManufacturingCosts
2347000
CY2022Q4 mnmd Accrued Clinical And Manufacturing Costs
AccruedClinicalAndManufacturingCosts
605000
CY2023Q3 mnmd Contribution Payable Current
ContributionPayableCurrent
2540000
CY2022Q4 mnmd Contribution Payable Current
ContributionPayableCurrent
1566000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1132000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
436000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9957000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5877000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 mnmd Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
40094708
CY2022Q2 mnmd Sale Of Equity Aggregate Public Offering Amount
SaleOfEquityAggregatePublicOfferingAmount
200000000
CY2023Q3 mnmd Sale Of Equity Aggregate Public Offering Additional Amount
SaleOfEquityAggregatePublicOfferingAdditionalAmount
62800000
CY2022Q3 mnmd Common Share And Warrant Public Offering Expire Date
CommonShareAndWarrantPublicOfferingExpireDate
2027-09-30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.38
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2190315
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.29
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4484000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
13333
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7333000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
21246
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
99454
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.51
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2056282
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24960000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1134101
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
25.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1453000
mnmd Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
13131
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
64719
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4226000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4286000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11818000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12331000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11000000
CY2023Q3 us-gaap Other Commitment
OtherCommitment
29400000
us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
The Term Loan bears a variable interest rate equal to the greater of (i) 10.95% and (ii) the sum of (a) the prime rate as reported in The Wall Street Journal plus (b) 2.95%.
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
200000
us-gaap Interest Expense Debt
InterestExpenseDebt
200000
CY2023Q3 mnmd Debt Repayments Of Principal In Year Two Before Unamortized Debt Issuance Cost
DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost
4522000
CY2023Q3 mnmd Debt Repayments Of Principal In Year Three Before Unamortized Debt Issuance Costs
DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts
6026000
CY2023Q3 mnmd Debt Repayments Of Principal In Year Four Before Unamortized Debt Issuance Costs
DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts
4452000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
932000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14068000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-058248-index-headers.html Edgar Link pending
0000950170-23-058248-index.html Edgar Link pending
0000950170-23-058248.txt Edgar Link pending
0000950170-23-058248-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnmd-20230930.htm Edgar Link pending
mnmd-20230930.xsd Edgar Link pending
mnmd-ex31_1.htm Edgar Link pending
mnmd-ex31_2.htm Edgar Link pending
mnmd-ex32_1.htm Edgar Link pending
mnmd-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
mnmd-20230930_cal.xml Edgar Link unprocessable
mnmd-20230930_def.xml Edgar Link unprocessable
mnmd-20230930_lab.xml Edgar Link unprocessable
mnmd-20230930_pre.xml Edgar Link unprocessable
mnmd-20230930_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending